Intact and cleaved uPAR forms: Diagnostic and prognostic value in cancer

Frontiers in Bioscience

Volumn 13, Issue 17, 2008, Pages 6752-6762

  Rasch, Morten G ^a   Lund, Ida K ^a   Almasi, Charlotte E ^a   Høyer Hansen, Gunilla ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Cancer; Diagnosis; Monoclonal antibodies; Plasminogen activation; Prognosis; Review; TR FIA; Upa; UPAR cleavage

Indexed keywords

CELL SURFACE RECEPTOR; PEPTIDE FRAGMENT; PLASMINOGEN; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTORS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTORS;

ENZYME ACTIVATION; FIBRINOLYSIS; HUMAN; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PROGNOSIS; REVIEW;

ENZYME ACTIVATION; FIBRINOLYSIS; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; PLASMINOGEN; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 52049092484     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. E. Rønne, N. Behrendt, V. Ellis, M. Ploug, K. Danø, G. Høyer-Hansen: Cell-induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2-terminal domain of the urokinase receptor. FEBS Lett 288 (1-2), 233-6 (1991)
2. V. Ellis, M.F. Scully, V.V. Kakkar: Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem 264 (4), 2185-8 (1989) (Pubitemid 19057691)
3. S. Liu, T.H. Bugge, S.H. Leppla: Targeting of tumor cells by cell surface urokinase plasminogen activatordependent anthrax toxin. J Biol Chem 276 (21), 17976-84 (2001)
4. H.M. Zhou, A. Nichols, P. Meda, J.D. Vassalli: Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis. EMBO J 19 (17), 4817-26 (2000)
5. P.A. Andreasen, R. Egelund, H.H. Petersen: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 57 (1), 25-40 (2000) (Pubitemid 30105328)
6. N. Behrendt: The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol Chem 385 (2), 103-36 (2004) (Pubitemid 38461334)
7. K. Danø, N. Behrendt, G. Høyer-Hansen, M. Johnsen, L.R. Lund, M. Ploug, J. Rømer: Plasminogen activation and cancer. Thromb Haemost 93 (4), 676-81 (2005) (Pubitemid 40485402)
8. M. Ploug: Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 9 (19), 1499-528 (2003) (Pubitemid 36758313)
9. G. Høyer-Hansen, E. Rønne, H. Solberg, N. Behrendt, M. Ploug, L.R. Lund, V. Ellis, K. Danø: Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 267 (25), 18224-9 (1992)
10. G. Høyer-Hansen, M. Ploug, N. Behrendt, E. Rønne, K. Danø: Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 243 (1-2), 21-6 (1997) (Pubitemid 27060380)
11. G. Høyer-Hansen, N. Behrendt, M. Ploug, K. Danø, K.T. Preissner: The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420 (1), 79-85 (1997) (Pubitemid 28037204)
12. C.E. Almasi, G. Høyer-Hansen, I.J. Christensen, K. Danø, H. Pappot: Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 48 (3), 349-55 (2005) (Pubitemid 40693620)
13. S. Mustjoki, N. Sidenius, C.F. Sier, F. Blasi, E. Elonen, R. Alitalo, A. Vaheri: Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 60 (24), 7126-32 (2000) (Pubitemid 32059194)
14. C.F. Sier, I. Nicoletti, M.L. Santovito, T. Frandsen, G. Aletti, A. Ferrari, A. Lissoni, R. Giavazzi, F. Blasi, N. Sidenius: Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost 91 (2), 403-11 (2004) (Pubitemid 38240188)
15. C. Selleri, N. Montuori, P. Ricci, V. Visconte, M.V. Carriero, N. Sidenius, B. Serio, F. Blasi, B. Rotoli, G. Rossi, P. Ragno: Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 105 (5), 2198-205 (2005) (Pubitemid 40731813)
16. N. Sidenius, C.F. Sier, F. Blasi: Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 475 (1), 52-6 (2000) (Pubitemid 30331077)
17. K. Wahlberg, G. Høyer-Hansen, B. Casslén: Soluble receptor for urokinase plasminogen activator in both fulllength and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res 58 (15), 3294-8 (1998) (Pubitemid 28371068)
18. O.G. Wilhelm, S. Wilhelm, G.M. Escott, V. Lutz, V. Magdolen, M. Schmitt, D.B. Rifkin, E.L. Wilson, H. Graeff, G. Brünner: Cellular glycosylphosphatidylinositolspecific phospholipase D regulates urokinase receptor shedding and cell surface expression. J Cell Physiol 180 (2), 225-35 (1999) (Pubitemid 29297199)
19. P. Llinas, M.H. Le Du, H. Gårdsvoll, K. Danø, M. Ploug, B. Gilquin, E.A. Stura, A. Ménèz: Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 24 (9), 1655-63 (2005) (Pubitemid 40704976)
20. Q. Huai, A.P. Mazar, A. Kuo, G.C. Parry, D.E. Shaw, J. Callahan, Y. Li, C. Yuan, C. Bian, L. Chen, B. Furie, B.C. Furie, D.B. Cines, M. Huang: Structure of human urokinase plasminogen activator in complex with its receptor. Science 311 (5761), 656-9 (2006) (Pubitemid 43191309)
21. C. Barinka, G. Parry, J. Callahan, D.E. Shaw, A. Kuo, K. Bdeir, D.B. Cines, A. Mazar, J. Lubkowski: Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol 363 (2), 482-95 (2006) (Pubitemid 44472493)
22. C. Yuan, M. Huang: Does the urokinase receptor exist in a latent form? Cell Mol Life Sci 64 (9), 1033-7 (2007) (Pubitemid 46684549)
23. N. Montuori, M.V. Carriero, S. Salzano, G. Rossi, P. Ragno: The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem 277 (49), 46932-9 (2002) (Pubitemid 36159197)
24. Y. Wei, D.A. Waltz, N. Rao, R.J. Drummond, S. Rosenberg, H.A. Chapman: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269 (51), 32380-8 (1994)
25. Y. Wei, J.A. Eble, Z. Wang, J.A. Kreidberg, H.A. Chapman: Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol Biol Cell 12 (10), 2975-86 (2001) (Pubitemid 33062955)
26. C.W. Crowley, R.L. Cohen, B.K. Lucas, G. Liu, M.A. Shuman, A.D. Levinson: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90 (11), 5021-5 (1993) (Pubitemid 23182967)
27. K. List, G. Høyer-Hansen, E. Rønne, K. Danø, N. Behrendt: Different mechanisms are involved in the antibody mediated inhibition of ligand binding to the urokinase receptor: a study based on biosensor technology. J Immunol Methods 222 (1-2), 125-33 (1999) (Pubitemid 29023709)
28. H. Lu, P. Yeh, J.D. Guitton, C. Mabilat, F. Desanlis, I. Maury, Y. Legrand, J. Soria, C. Soria: Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the Nterminal fragment of human urokinase and human albumin. FEBS Lett 356 (1), 56-9 (1994) (Pubitemid 24374032)
29. T. Luther, V. Magdolen, S. Albrecht, M. Kasper, C. Riemer, H. Kessler, H. Graeff, M. Müller, M. Schmitt: Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 150 (4), 1231-44 (1997) (Pubitemid 27152642)
30. H.Y. Min, L.V. Doyle, C.R. Vitt, C.L. Zandonella, J.R. Stratton-Thomas, M.A. Shuman, S. Rosenberg: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56 (10), 2428-33 (1996) (Pubitemid 26154094)
31. M. Ploug, S. Østergaard, H. Gårdsvoll, K. Kovalski, C. Holst-Hansen, A. Holm, L. Ossowski, K. Danø: Peptidederived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 40 (40), 12157-68 (2001) (Pubitemid 32946557)
32. N. Schmiedeberg, M. Schmitt, C. Rölz, V. Truffault, M. Sukopp, M. Bürgle, O.G. Wilhelm, W. Schmalix, V. Magdolen, H. Kessler: Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J Med Chem 45 (23), 4984-94 (2002) (Pubitemid 35278694)
33. R.J. Tressler, P.A. Pitot, J.R. Stratton, L.D. Forrest, S. Zhuo, R.J. Drummond, S. Fong, M.V. Doyle, L.V. Doyle, H.Y. Min, S. Rosenberg: Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS 107 (1), 168-73 (1999) (Pubitemid 29133537)
34. C. Pyke, N. Graem, E. Ralfkiær, E. Rønne, G. Høyer- Hansen, N. Brünner, K. Danø: Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 53 (8), 1911-5 (1993) (Pubitemid 23127124)
35. C. Pyke, E. Ralfkiær, E. Rønne, G. Høyer-Hansen, L. Kirkeby, K. Danø: Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 24 (2), 131-8 (1994) (Pubitemid 24192274)
36. S. Ganesh, C.F. Sier, M.M. Heerding, G. Griffioen, C.B. Lamers, H.W. Verspaget: Urokinase receptor and colorectal cancer survival. Lancet 344 (8919), 401-2 (1994) (Pubitemid 24248215)
37. J. Grøndahl-Hansen, H.A. Peters, W.L. van Putten, M.P. Look, H. Pappot, E. Rønne, K. Danø, J.G. Klijn, N. Brünner, J.A. Foekens: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1 (10), 1079-87 (1995)
38. M. Kotzsch, T. Luther, N. Harbeck, D. Ockert, V. Lutz, F. Noack, D. Grossmann, S. Albrecht, M.D. Kramer, A. Lossnitzer, M. Grosser, M. Schmitt, V. Magdolen: New ELISA for quantitation of human urokinase receptor (CD87) in cancer. Int J Oncol 17 (4), 827-34 (2000)
39. H. Pedersen, N. Brünner, D. Francis, K. Osterlind, E. Rønne, H.H. Hansen, K. Danø, J. Grøndahl-Hansen: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54 (17), 4671-5 (1994) (Pubitemid 24276492)
40. R. Riisbro, I.J. Christensen, T. Piironen, M. Greenall, B. Larsen, R.W. Stephens, C. Han, G. Høyer-Hansen, K. Smith, N. Brünner, A.L. Harris: Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 8 (5), 1132-41 (2002) (Pubitemid 34517650)
41. R.W. Stephens, H.J. Nielsen, I.J. Christensen, O. Thorlacius-Ussing, S. Sorensen, K. Danø, N. Brünner: Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91 (10), 869-74 (1999) (Pubitemid 29252303)
42. P. Ragno, N. Montuori, B. Covelli, G. Høyer-Hansen, G. Rossi: Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells. Cancer Res 58 (6), 1315-9 (1998) (Pubitemid 28183224)
43. H. Solberg, J. Rømer, N. Brünner, A. Holm, N. Sidenius, K. Danø, G. Høyer-Hansen: A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 58 (6), 877-81 (1994) (Pubitemid 24306380)
44. G. Høyer-Hansen, H. Solberg, E. Rønne, N. Behrendt, K. Danø: Variants of the receptor for urokinase-type plasminogen activator. In: Biology of Vitronectins and their receptors. Eds: K.T. Preissner, S. Rosenblatt, C. Kost, J. Wegerhoff, D.F. Mosher, Elsevier Science Publishers B.V, The Netherlands (1993)
45. R. Mazzieri, G. Høyer-Hansen, E. Rønne, P. Vagnarelli, E. Raimondi, De Carli L., K. Danø, P. Mignatti: Urokinase and urokinase receptor expression in somatic cell hybrids. Fibrinolysis 8, 344-52 (1994) (Pubitemid 24344378)
46. G. Høyer-Hansen, I.K. Lund: Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 44, 65-102 (2007)
47. T. Piironen, B. Laursen, J. Pass, K. List, H. Gårdsvoll, M. Ploug, K. Danø, G. Høyer-Hansen: Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor. Clin Chem 50 (11), 2059-68 (2004) (Pubitemid 39425843)
48. T. Piironen, A. Haese, H. Huland, T. Steuber, I.J. Christensen, N. Brünner, K. Danø, G. Høyer-Hansen, H. Lilja: Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. Clin Chem 52 (5), 838-44 (2006) (Pubitemid 43673262)
49. L. Sottrup-Jensen, M. Zajdel, H. Claeys, T.E. Petersen, S. Magnusson: Amino-acid sequence of activation cleavage site in plasminogen: homology with "pro" part of prothrombin. Proc Natl Acad Sci U S A 72 (7), 2577-81 (1975)
50. L. Summaria, B. Hsieh, K.C. Robbins: The specific mechanism of activation of human plasminogen to plasmin. J Biol Chem 242 (19), 4279-83 (1967)
51. S.H. Ke, G.S. Coombs, K. Tachias, D.R. Corey, E.L. Madison: Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 272 (33), 20456-62 (1997) (Pubitemid 27355599)
52. H. Solberg, D. Løber, J. Eriksen, M. Ploug, E. Rønne, N. Behrendt, K. Danø, G. Høyer-Hansen: Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. Eur J Biochem 205 (2), 451-8 (1992)
53. H. Gårdsvoll, M. Ploug: Mapping of the vitronectin binding site on the urokinase receptor. Involvement of a coherent receptor interface comprising residues from both domain I and the flanking interdomain linker region. J Biol Chem 274 (53), 37995-38003 (2007)
54. H. Gårdsvoll, B. Gilquin, M.H. Le Du, A. Ménèz, T.J. Jørgensen, M. Ploug: Characterization of the functional epitope on the urokinase receptor. Complete alanine scanning mutagenesis supplemented by chemical cross-linking. J Biol Chem 281 (28), 19260-72 (2006) (Pubitemid 44035430)
55. I. Bolon, H.M. Zhou, Y. Charron, A. Wohlwend, J.D. Vassalli: Plasminogen mediates the pathological effects of urokinase-type plasminogen activator overexpression. Am J Pathol 164 (6), 2299-304 (2004) (Pubitemid 38669375)
56. G. Høyer-Hansen, U. Pessara, A. Holm, J. Pass, U. Weidle, K. Danø, N. Behrendt: Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor. Biochem J 358 (Pt 3), 673-9 (2001) (Pubitemid 32896955)
57. T. Kukulansky, S. Abramovitch, N. Hollander: Cleavage of the glycosylphosphatidylinositol anchor affects the reactivity of thy-1 with antibodies. J Immunol 162 (10), 5993-7 (1999) (Pubitemid 29314956)
58. A. English, R. Kosoy, R. Pawlinski, A. Bamezai: A monoclonal antibody against the 66-kDa protein expressed in mouse spleen and thymus inhibits Ly-6A.2-dependent cell-cell adhesion. J Immunol 165 (7), 3763-71 (2000) (Pubitemid 32057282)
59. H. Durbin, S. Young, L.M. Stewart, F. Wrba, A.J. Rowan, D. Snary, W.F. Bodmer: An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc Natl Acad Sci USA 91 (10), 4313-7 (1994) (Pubitemid 24143423)
60. P. Bütikofer, T. Malherbe, M. Boschung, I. Roditi: GPI-anchored proteins: now you see 'em, now you don't. FASEB J 15 (2), 545-8 (2001) (Pubitemid 32141446)
61. J. Pass, A. Jögi, I.K. Lund, B. Rønø, M.G. Rasch, H. Gårdsvoll, L.R. Lund, M. Ploug, J. Rømer, K. Danø, G. Høyer-Hansen: Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptormediated uPA activity in vitro and in vivo. Thromb Haemost 97 (6), 1013-22 (2007) (Pubitemid 46939216)
62. M.G. Rasch: Generation and characterization of murine monoklonal antibodies against the murine form of urokinase plasminogen activator receptor (uPAR). Master Thesis, 1-98 (2007)
63. E. Rønne, N. Behrendt, M. Ploug, H.J. Nielsen, E. Wollisch, U. Weidle, K. Danø, G. Høyer-Hansen: Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J Immunol Methods 167 (1-2), 91-101 (1994) (Pubitemid 24053776)
64. N. Behrendt, M. Ploug, L. Patthy, G. Houen, F. Blasi, K. Danø: The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 266 (12), 7842-7 (1991) (Pubitemid 21906442)
65. Q. Huai, A.P. Mazar, A. Kuo, G.C. Parry, D.E. Shaw, J. Callahan, Y. Li, C. Yuan, C. Bian, L. Chen, B. Furie, B.C. Furie, D.B. Cines, M. Huang: Structure of human urokinase plasminogen activator in complex with its receptor. Science 311 (5761), 656-9 (2006) (Pubitemid 43191309)
66. N. Behrendt, E. Rønne, M. Ploug, T. Petri, D. Løber, L.S. Nielsen, W.D. Schleuning, F. Blasi, E. Appella, K. Danø: The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 265 (11), 6453-60 (1990)
67. H. Gårdsvoll, H. Solberg, K. Danø, G. Høyer-Hansen: Generation of high-affinity rabbit polyclonal antibodies to the murine urokinase receptor using DNA immunization. J Immunol Methods 234 (1-2), 107-16 (2000) (Pubitemid 30084804)
68. N. Sidenius, F. Blasi: Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett 470 (1), 40-6 (2000) (Pubitemid 30155620)
69. D. Olson, J. Pöllänen, G. Høyer-Hansen, E. Rønne, K. Sakaguchi, T.C. Wun, E. Appella, K. Danø, F. Blasi: Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J Biol Chem 267 (13), 9129-33 (1992)
70. R.P. Czekay, T.A. Kuemmel, R.A. Orlando, M.G. Farquhar: Direct Binding of Occupied Urokinase Receptor (uPAR) to LDL Receptor-related Protein Is Required for Endocytosis of uPAR and Regulation of Cell Surface Urokinase Activity. Mol Biol Cell 12 (5), 1467-79 (2001) (Pubitemid 33044425)
71. A. Nykjaer, L. Kjøller, R.L. Cohen, D.A. Lawrence, B.A. Garni-Wagner, R.F. Todd, III, A.J. van Zonneveld, J. Gliemann, P.A. Andreasen: Regions involved in binding of urokinase-type-1 inhibitor complex and pro-urokinase to the endocytic alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Evidence that the urokinase receptor protects pro-urokinase against binding to the endocytic receptor. J Biol Chem 269 (41), 25668-76 (1994)
72. A.M. Bernstein, S.S. Twining, D.J. Warejcka, E. Tall, S.K. Masur: Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation. Mol Biol Cell 18 (7), 2716-27 (2007) (Pubitemid 47025736)
73. D. Liu, G.J. Aguirre, Y. Estrada, L. Ossowski: EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1 (5), 445-57 (2002) (Pubitemid 41039125)
74. R. Mazzieri, S. D'Alessio, R.K. Kenmoe, L. Ossowski, F. Blasi: An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol Biol Cell 17 (1), 367-78 (2006) (Pubitemid 43049489)
75. M. Resnati, M. Guttinger, S. Valcamonica, N. Sidenius, F. Blasi, F. Fazioli: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15 (7), 1572-82 (1996) (Pubitemid 26112379)
76. M. Resnati, I. Pallavicini, J.M. Wang, J. Oppenheim, C.N. Serhan, M. Romano, F. Blasi: The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R. Proc Natl Acad Sci USA 99 (3), 1359-64 (2002) (Pubitemid 34136498)
77. F. Fazioli, M. Resnati, N. Sidenius, Y. Higashimoto, E. Appella, F. Blasi: A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 16 (24), 7279-86 (1997) (Pubitemid 28010488)
78. C. Selleri, N. Montuori, P. Ricci, V. Visconte, A. Baiano, M.V. Carriero, B. Rotoli, G. Rossi, P. Ragno: In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer. Cancer Res 66 (22), 10885-90 (2006) (Pubitemid 44876986)
79. G. Høyer-Hansen, M.J. Hamers, A.N. Pedersen, H.J. Nielsen, N. Brünner, K. Danø, R.W. Stephens: Loss of ELISA specificity due to biotinylation of monoclonal antibodies. J Immunol Methods 235 (1-2), 91-9 (2000) (Pubitemid 30089787)
80. R.W. Stephens, A.N. Pedersen, H.J. Nielsen, M.J. Hamers, G. Høyer-Hansen, E. Rønne, E. Dybkjær, K. Danø, N. Brünner: ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43 (10), 1868-76 (1997) (Pubitemid 27452275)
81. R. Riisbro, T. Piironen, N. Brünner, B. Larsen, H.J. Nielsen, R.W. Stephens, G. Høyer-Hansen: Measurement of soluble urokinase plasminogen activator receptor in serum. J Clin Ligand Assay 25 (1), 53-6 (2002) (Pubitemid 34984724)
82. R. Riisbro, I.J. Christensen, H.J. Nielsen, N. Brünner, M. Nilbert, E. Fernebro: Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration. Int J Biol Markers 20 (2), 93-102 (2005) (Pubitemid 41052454)
83. D.Q. Seetoo, P.J. Crowe, P.J. Russell, J.L. Yang: Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 82 (3), 184-93 (2003) (Pubitemid 36278267)
84. M.M. Skelly, A. Troy, M.J. Duffy, H.E. Mulcahy, C. Duggan, T.G. Connell, D.P. O'Donoghue, K. Sheahan: Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome. Clin Cancer Res 3 (10), 1837-40 (1997) (Pubitemid 27444725)
85. S.F. Shariat, C.G. Roehrborn, J.D. McConnell, S. Park, N. Alam, T.M. Wheeler, K.M. Slawin: Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol 25 (4), 349-55 (2007) (Pubitemid 350002982)
86. B. Werle, M. Kotzsch, T.T. Lah, J. Kos, D. Gabrijelcic-Geiger, E. Spiess, J. Schirren, W. Ebert, W. Fiehn, T. Luther, V. Magdolen, M. Schmitt, N. Harbeck: Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogen activator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 24 (6), 4147-61 (2004) (Pubitemid 40468721)
87. F. Blasi, P. Carmeliet: uPAR: a versatile signaling orchestrator. Nat Rev Mol Cell Biol 3 (12), 932-43 (2002)
88. N. Montuori, V. Visconte, G. Rossi, P. Ragno: Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules? Thromb Haemost 93 (2), 192-8 (2005) (Pubitemid 40253721)
89. J. Rømer, B.S. Nielsen, M. Ploug: The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 10 (19), 2359-76 (2004) (Pubitemid 38855042)
90. U. Reuning, S. Sperl, C. Kopitz, H. Kessler, A. Krüger, M. Schmitt, V. Magdolen: Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr Pharm Des 9 (19), 1529-43 (2003) (Pubitemid 36758314)
91. N. Sidenius, F. Blasi: The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22 (2-3), 205-22 (2003) (Pubitemid 36561058)
92. K. Almholt, L.R. Lund, J. Rygaard, B.S. Nielsen, K. Danø, J. Rømer, M. Johnsen: Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 113 (4), 525-32 (2005) (Pubitemid 40038727)
93. I.K. Lund, A. Jögi, B. Rønø, M.G. Rasch, L.R. Lund, K. Almholt, H. Gårdsvoll, N. Behrendt, J. Rømer, G. Høyer-Hansen: Antibody-mediated targeting of the uPA proteolytic function neutralizes fibrinolysis in vivo. J Biol Chem, submitted (2008)
94. A. Jögi, J. Pass, G. Høyer-Hansen, L.R. Lund, B.S. Nielsen, K. Danø, J. Rømer: Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice. J Thromb Haemost 5 (9), 1936-44 (2007) (Pubitemid 47288953)